PDRN is everywhere on labels, but most human evidence comes from injections and microneedling. Here is what a 2026 review and one split-face topical trial actually show.
· 4 min read
PDRN has gone from a clinic term to a line on serum labels, and search interest follows it. The name stands for polydeoxyribonucleotide, a mixture of DNA fragments. Marketing copy often implies that a cream containing it does what an injection does. The research is more careful than that. Most of the human evidence comes from injections and procedures, and the one topical study found for this article is a single small split-face trial on eye-area skin, run with ingredient and retinol supplied by manufacturers.
PDRN is a mixture of deoxyribonucleotides with molecular weights ranging from 50 to 1,500 kDa. In the pharmaceutical form described in a 2017 review in Frontiers in Pharmacology, it is derived from a controlled purification and sterilization process of DNA from salmon trout or chum salmon sperm, a process that aims to leave no active protein or peptides that could cause immune reactions. 'PDRN' on a cosmetic label can therefore refer to a drug-grade material or to a cosmetic-grade extract, and a label rarely says which. Plant-derived versions marketed as phyto-PDRN also exist, and they are a different material from the salmon-derived one in the literature below.
The same review reports that experiments in cells and animals suggest PDRN's most relevant mechanism is engagement of adenosine A2A receptors, which is linked to the DNA's origin, molecular weight and manufacturing process. PDRN also supplies nucleosides and nucleotides to what is called the salvage pathway, a way cells recycle building blocks. This is why you will see PDRN described as pro-repair. But those findings come mostly from lab and drug-development settings, not from skincare lotions.
A 2026 systematic review in Cureus searched PubMed, Embase and CENTRAL through January 2026 for randomized trials of polynucleotides and PDRN in skin rejuvenation, scar prevention and wound healing. It found only seven trials with 183 participants in total: four on skin rejuvenation, one on postoperative scars and two on wound healing. The authors reported improved wrinkle-related outcomes, scar quality and patient-reported satisfaction, with no serious treatment-related adverse events. The most consistent benefits appeared in wound-healing settings.
Several points temper that. The review itself says the evidence is limited by small sample sizes, different protocols and varied outcome measures, and that the lack of standardized preparations limited what could be compared. One of the included studies paired PDRN with microneedling in 24 women, 12 per group, and compared it with microneedling plus platelet-rich plasma, so it is not a test of PDRN alone. Another used topical polynucleotide after radiofrequency microneedling, in 29 women. In short, the strongest trial evidence involves procedures that break the skin barrier, which is very different from smoothing a serum onto intact skin.
A 2026 paper in PLoS One tested a medium-length PDRN preparation, described as salmon-derived with a molecular weight of no more than 850 kDa, in several ways. In cell experiments, it activated signaling pathways linked to collagen production. In UV-irradiated ex vivo human skin, it increased viable epidermal thickness and raised several collagens and elastic-fiber-related proteins. In a randomized, double-blind, split-face study, 0.1% PDRN eye cream was compared with 0.1% retinol over 28 days. The authors reported roughly two-fold greater improvements in periocular wrinkles, dermal thickness, density and eye-bag measures with PDRN than with retinol, with good tolerability.
That is an interesting result, and it is also worth reading cautiously. The paper itself notes that Raman spectroscopy cannot tell exogenous PDRN apart from the skin's own nucleic acids, so how far the ingredient travels is not settled. The PDRN was provided by a manufacturer, and the retinol came from another supplier. It is a 28-day trial on a single skin area, and the sample size is not something this article can verify beyond what the paper reports. It needs replication by independent groups before anyone should call PDRN a retinol alternative.
PDRN has a plausible mechanism, a decent amount of procedure-based research, and one promising but small and early topical trial. What it does not have is a body of independent evidence showing that a serum does what clinic procedures do. If you want to try it, treat it as an addition to a routine that already includes sunscreen and a moisturizer, patch test first, and judge it over eight to twelve weeks rather than days. If a product page promises results equal to an injection, the research does not support that claim.
Rituelle reads your skin over time and adapts your routine to it.
Join the waitlist
Ingredients
PDRN, the DNA-fragment ingredient behind a wave of firming-skin claims, has a small tolerance case series, animal data and delivery research. Here is what that does and does not add up to.
5 min read
Ingredients
Searches for niacinamide supplements are rising alongside serums. Here is what 2% topical studies show, what the high-dose oral trials were really about, and how to read the label.
5 min read
Decoding Labels
Tone-up creams are still around, but a pink brightening base is not automatically sun protection. Three label checks, grounded in FDA guidance, separate real sunscreen from makeup.
5 min read
